Cagrilintide
Also known as: NN9838
A long-acting amylin analog being developed in combination with semaglutide (CagriSema) for obesity and type 2 diabetes treatment.
Mechanism of Action
Activates amylin receptors in the brain to promote satiety, slow gastric emptying, and suppress glucagon secretion. Complementary pathway to GLP-1.
Dosing Protocol
Titrated from 0.25mg weekly up to 2.4mg weekly. Often combined with semaglutide.
Open peptide calculatorReconstitution
Research-grade: 10mg vial + 2mL BAC water.
Storage
Refrigerate 2-8°C.
Side Effects
- ●Nausea
- ●Injection site reactions
- ●Diarrhea
Key Research Findings
- ●CagriSema combination: ~15.6% weight loss at 32 weeks
- ●Additive effects with GLP-1 agonists on appetite suppression
- ●Improved postprandial glucose control
Latest Verified Lab Report
No lab reports available for Cagrilintide yet.
Community-funded testing results will appear here.
Vendor Trust Leaderboard
Trust leaderboard coming soon.
Vendor rankings based on verified lab test results.
Research Use Only
This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.